Physician profile
Christopher Ruzicka
NPI 1992813414
$4,621.58
in general payments reported to CMS, 2019-2025
9 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $119 · 2022: $1,871 · 2023: $257 · 2024: $377 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,232 · Food and Beverage: $1,028 · Entertainment: $242 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,231.54 |
| Food and Beverage | $1,028.04 |
| Entertainment | $241.58 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,206.29 | 2022-2025 | Acuvue |
| Coopervision INC. | $289.41 | 2024-2025 | Myday Contact Lens |
| Optos, INC. | $241.58 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $240.26 | 2023-2024 | Infuse Multifocal, Infuse |
| Glaukos Corporation | $222.22 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $221.23 | 2019-2021 | |
| Genentech USA, INC. | $122.31 | 2023 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $40.01 | 2024 | Cirrus Hd-Oct, Clarus |
| Alcon Vision LLC | $38.27 | 2019-2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ruzicka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.